



## Temozolomide Injection Formulation

Version 4.2      Revision Date: 05/17/2017      SDS Number: 27582-00007      Date of last issue: 10/26/2016  
 Date of first issue: 11/03/2014

H341 Suspected of causing genetic defects.  
 H351 Suspected of causing cancer.  
 H360FD May damage fertility. May damage the unborn child.  
 H372 Causes damage to organs (Bone marrow, thymus gland, lymph node, spleen) through prolonged or repeated exposure if swallowed.

Precautionary Statements :

**Prevention:**

P201 Obtain special instructions before use.  
 P202 Do not handle until all safety precautions have been read and understood.  
 P260 Do not breathe dust.  
 P264 Wash skin thoroughly after handling.  
 P270 Do not eat, drink or smoke when using this product.  
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P301 + P310 + P330 IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth.  
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

Dust contact with the eyes can lead to mechanical irritation.  
 Contact with dust can cause mechanical irritation or drying of the skin.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

**Hazardous ingredients**

Chemical name	CAS-No.	Concentration (% w/w)
Temozolomide	85622-93-1	>= 5 - < 10
Hydrochloric acid	7647-01-0	>= 3 - < 5

### SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention.

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/26/2016
4.2	05/17/2017	27582-00007	Date of first issue: 11/03/2014

---

- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Call a physician or poison control center immediately.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.  
Toxic if swallowed.  
Suspected of causing genetic defects.  
Suspected of causing cancer.  
May damage fertility. May damage the unborn child.  
Causes damage to organs through prolonged or repeated exposure if swallowed.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists.
- Notes to physician : Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides  
Chlorine compounds
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/26/2016
4.2	05/17/2017	27582-00007	Date of first issue: 11/03/2014

---

so.  
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

## Temozolomide Injection Formulation

Version 4.2      Revision Date: 05/17/2017      SDS Number: 27582-00007      Date of last issue: 10/26/2016  
 Date of first issue: 11/03/2014

environment.

Conditions for safe storage : Keep in properly labeled containers.  
 Store locked up.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Organic peroxides  
 Explosives  
 Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Temozolomide	85622-93-1	TWA	0.6 µg/m <sup>3</sup>	Merck
		Wipe limit	6 µg/100 cm <sup>2</sup>	Merck
Hydrochloric acid	7647-01-0	C	2 ppm	ACGIH
		C	5 ppm 7 mg/m <sup>3</sup>	NIOSH REL
		C	5 ppm 7 mg/m <sup>3</sup>	OSHA Z-1

**Engineering measures** : Minimize workplace exposure concentrations.  
 Apply measures to prevent dust explosions.  
 Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).  
 Use with local exhaust ventilation.  
 Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m<sup>3</sup> - total dust, 5 mg/m<sup>3</sup> - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m<sup>3</sup> - respirable particles, 10 mg/m<sup>3</sup> - inhalable particles.

#### Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/26/2016
4.2	05/17/2017	27582-00007	Date of first issue: 11/03/2014

---

by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection		
Material	:	Chemical-resistant gloves
Material	:	Chemical-resistant gloves
Remarks	:	Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Eye protection	:	Wear the following personal protective equipment: Safety goggles
Skin and body protection	:	Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Hygiene measures	:	Ensure that eye flushing systems and safety showers are located close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	white
Odor	:	No information available.
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available



## Temozolomide Injection Formulation

Version      Revision Date:      SDS Number:      Date of last issue: 10/26/2016  
4.2          05/17/2017          27582-00007      Date of first issue: 11/03/2014

---

Hazardous decomposition products : No hazardous decomposition products are known.

---

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Toxic if swallowed.

#### Product:

Acute oral toxicity : LD50 (Dog): 237.5 mg/kg  
LD50 (Rat): 3,938 mg/kg  
LD50 (Mouse): 2,563 mg/kg

#### Ingredients:

##### Temozolomide:

Acute oral toxicity : LD50 (Dog): 19 mg/kg  
LD50 (Rat): 315 mg/kg  
LD50 (Mouse): 205 mg/kg

##### Hydrochloric acid:

Acute inhalation toxicity : LC50 (Rat): 8.3 mg/l  
Exposure time: 30 min  
Test atmosphere: dust/mist

#### Skin corrosion/irritation

Not classified based on available information.

#### Ingredients:

##### Hydrochloric acid:

Species: Rabbit  
Method: OECD Test Guideline 404  
Result: Corrosive after 3 minutes to 1 hour of exposure

#### Serious eye damage/eye irritation

Not classified based on available information.

#### Ingredients:

##### Hydrochloric acid:

Species: Rabbit  
Result: Irreversible effects on the eye



## Temozolomide Injection Formulation

Version 4.2      Revision Date: 05/17/2017      SDS Number: 27582-00007      Date of last issue: 10/26/2016  
 Date of first issue: 11/03/2014

---

### Ingredients:

#### **Temozolomide:**

Species: Rat  
 Application Route: Oral  
 Exposure time: 6 Months  
 4 mg/kg body weight  
 Result: positive  
 Target Organs: Mammary gland

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in animal studies

#### **Hydrochloric acid:**

Species: Rat  
 Application Route: Inhalation  
 Exposure time: 128 weeks  
 Result: negative

#### **IARC**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

#### **OSHA**

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

#### **NTP**

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### **Reproductive toxicity**

May damage fertility. May damage the unborn child.

### Ingredients:

#### **Temozolomide:**

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat, male  
 Application Route: Oral  
 Fertility: LOAEL: 8.5 mg/kg body weight  
 Result: positive

Effects on fetal development : Test Type: Embryo-fetal development  
 Species: Rat  
 Application Route: Oral  
 Embryo-fetal toxicity.: LOAEL: 13 mg/kg body weight  
 Result: positive, Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

## Temozolomide Injection Formulation

Version      Revision Date:      SDS Number:      Date of last issue: 10/26/2016  
4.2          05/17/2017          27582-00007      Date of first issue: 11/03/2014

---

### STOT-single exposure

Not classified based on available information.

#### Ingredients:

##### Hydrochloric acid:

Assessment: May cause respiratory irritation.

### STOT-repeated exposure

Causes damage to organs (Bone marrow, thymus gland, lymph node, spleen) through prolonged or repeated exposure if swallowed.

#### Ingredients:

##### Temozolomide:

Routes of exposure: Ingestion

Target Organs: Bone marrow, thymus gland, lymph node, spleen

Assessment: Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Ingredients:

##### Temozolomide:

Species: Rat, female

NOAEL: 4 mg/kg

LOAEL: 21 mg/kg

Application Route: Oral

Exposure time: 6 Months

Target Organs: lymph node, thymus gland, Bone marrow, Reproductive organs

Species: Rat, male

NOAEL: 8.5 mg/kg

LOAEL: 34 mg/kg

Application Route: Oral

Exposure time: 6 Months

Target Organs: lymph node, thymus gland, Bone marrow, male reproductive organs, Gastrointestinal tract

Species: Dog

NOAEL: 2.5 mg/kg

LOAEL: 6.3 mg/kg

Application Route: Oral

Exposure time: 6 Months

Target Organs: Bone marrow, spleen, male reproductive organs, Gastrointestinal tract, thymus

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Ingredients:

##### Temozolomide:

Ingestion : Symptoms: Blood disorders, Nausea, Vomiting, Diarrhea,

## Temozolomide Injection Formulation

Version 4.2      Revision Date: 05/17/2017      SDS Number: 27582-00007      Date of last issue: 10/26/2016  
Date of first issue: 11/03/2014

---

anorexia, Fatigue, hair loss

---

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Ingredients:

##### **Temozolomide:**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h
- Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 90 mg/l  
Exposure time: 72 h
- NOEC (Pseudokirchneriella subcapitata (green algae)): 40 mg/l  
Exposure time: 72 h
- Toxicity to microorganisms : EC50: > 100 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

#### Persistence and degradability

##### Ingredients:

##### **Temozolomide:**

- Biodegradability : Result: rapidly degradable  
Biodegradation: 83 %  
Exposure time: 35 d
- Stability in water : Degradation half life (DT50): < 1 d

#### Bioaccumulative potential

##### Ingredients:

##### **Temozolomide:**

- Partition coefficient: n-octanol/water : log Pow: 1.35

#### Mobility in soil

No data available

#### Other adverse effects

No data available

## Temozolomide Injection Formulation

Version      Revision Date:      SDS Number:      Date of last issue: 10/26/2016  
4.2            05/17/2017            27582-00007      Date of first issue: 11/03/2014

### SECTION 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues            :    Dispose of in accordance with local regulations.

Contaminated packaging        :    Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

Not regulated as a dangerous good

##### IATA-DGR

Not regulated as a dangerous good

##### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

##### 49 CFR

Not regulated as a dangerous good

### SECTION 15. REGULATORY INFORMATION

#### EPCRA - Emergency Planning and Community Right-to-Know

##### CERCLA Reportable Quantity

Ingredients	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
Hydrochloric acid	7647-01-0	5000	108695

##### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

##### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards**            :    Fire Hazard  
Acute Health Hazard  
Chronic Health Hazard

**SARA 313**                            :    This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

## Temozolomide Injection Formulation

Version 4.2      Revision Date: 05/17/2017      SDS Number: 27582-00007      Date of last issue: 10/26/2016  
 Date of first issue: 11/03/2014

### US State Regulations

#### Pennsylvania Right To Know

D-mannitol	69-65-8
Sodium citrate, dihydrate	6132-04-3
L-Threonine	72-19-5
Polyethylene glycol sorbitan monooleate	9005-65-6
Temozolomide	85622-93-1
Hydrochloric acid	7647-01-0

#### California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

#### California List of Hazardous Substances

Hydrochloric acid	7647-01-0
-------------------	-----------

#### California Permissible Exposure Limits for Chemical Contaminants

Hydrochloric acid	7647-01-0
-------------------	-----------

#### California List of Acutely Hazardous Chemicals, Toxics and Reactives

Hydrochloric acid	7647-01-0
-------------------	-----------


#### The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

## SECTION 16. OTHER INFORMATION

### Further information

#### NFPA:



#### HMIS® IV:

HEALTH	*	3
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
-------	---	---

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/26/2016
4.2	05/17/2017	27582-00007	Date of first issue: 11/03/2014

---

NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / C	:	Ceiling limit
NIOSH REL / C	:	Ceiling value not be exceeded at any time.
OSHA Z-1 / C	:	Ceiling

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a>
--	---	---

Revision Date	:	05/17/2017
---------------	---	------------

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified

## Temozolomide Injection Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/26/2016
4.2	05/17/2017	27582-00007	Date of first issue: 11/03/2014

---

in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8